HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400-HIV-RNA cp/ml) during different antiretroviral regimes

Current HIV Research

Volumn 6, Issue 3, 2008, Pages 261-266

  Nicastri, Emanuele ^a   Palmisano, Lucia ^b   Sarmati, Loredana ^c   D'Ettorre, Gabriella ^d   Parisi, Saverio ^e   Andreotti, Mauro ^b   Buonomini, Annarita ^c   Pirillo, Franca M ^b   Narciso, Pasquale ^a   Bellagamba, Rita ^a   Vullo, Vincenzo ^b   Montano, Marco ^c   Di Perri, Giovanni ^f   Andreoni, Massimo ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

CD4 cell count; HIV 1 replication; Non nucleoside reverse transcriptase inhibitor; Nucleoside reverse transcriptase inhibitors; Peripheral blood mononuclear cells

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; TREATMENT DURATION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DNA, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIREMIA; VIRUS REPLICATION;

EID: 47749112849     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208784325010     Document Type: Review

References (26)

1. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7.
2. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77: 11212-9.
3. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure Proc Natl Acad Sci USA 1997; 94: 12574-9.
4. Hatzakis AE, Toulomi G, Pantazis N. Cellular HIV-1-1 DNA load predicts HIV-1-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004; 18: 2261-7.
5. Pellegrin I, Caumont A, Garrigue I. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187:38-46.
6. Palmisano L, Giuliano M, Nicastri E. et al. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005; 19: 1843-7.
7. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1-1 DNA level. AIDS 2004; 18: 45-9.
8. Stanley SK, Ostrowski MA, Justement JS, et al. Recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996 334: 1222-1230.
9. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83-91.
10. Chun TW, Nickle DC, Justement JS, et al. HIV-1-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115: 3250-5.
11. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J AIDS 2007; 45: 483-93.
12. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet. 2006; 368: 2125-2135.
13. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as inital therapy for HIV-1 infection, N Engl J Med 2003; 249: 2293-2303.
14. INITIO Trial International Coordinating Committee, Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO; open-label randomised trial, Lancet 2006; 368: 287-299.
15. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. XVI International AIDS Conference. August 13-18, 2006. Toronto. Abstract THLB0204.
16. Haubrich RH, Riddler S, Ribaudo H, et al. Initial Viral Decay to Assess the Relative Antiretroviral Potency of PI-, NNRTI-, and NRTI-Sparing Regimens for First Line Therapy of HIV-1-1 Infection: ACTG 5160s (sub-study of A5142), xIv CROI, February 25-28, 2007. Los Angeles, Abs 137.
17. Torti C, Maggiolo F, Patroni A, Suter F, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-1-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother 2005; 56: 190-5.
18. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV-1 infection. AIDS 2004; 18: 1895-904.
19. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-1-infected veterans starting combination antiretroviral therapies. AIDS 2007; 21: 1579-1589.
20. De Luca A, Cozzi-Lepri A, Antinori A, et al. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir Ther 2006; 11: 609-18.
21. Havlir DV, Koelsch KK, Strain MC, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191: 1154-1158.
22. McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS 2006; 20: 2331-2335
23. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on Antiretroviral Therapy. J Acquir Immune Defic Syndr 2007; 45: 483-493.
24. Landay AL, Spritzler J, Kessler H, et al. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis 2003; 188: 1444-1454.
25. Vlahakis SR, Bennett SA, Whitehead SN, Badley AD. HIV-1 protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis. 2007; 12: 969-977.
26. Commissione Nazionale per la Lotta Contro l'AIDS e le Altre Malattie Infettive Emergenti e Riemergenti. Aggiornamento sulle conoscenze in tema di terapia antiretrovirale. http://www.infettivebrscia.it/ schede_HIV/LineeGuida/aggiomanientoterapieantiretrovirali. pdf. (15 October 2007, date last access).